(Q37830371)

English

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

scientific article published on 20 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

based on heuristic

inferred from title

Kathleen I. Pritchard

object named as

Kathleen I Pritchard

4

0 references

author name string

Susan F Dent

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Rania Gaspo

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Michelle Kissner

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

20 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

126

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

295-310

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

https://scigraph.springernature.com/pub.10.1007/s10549-011-1351-3

0 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Advances in adjuvant endocrine therapy for postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Adherence to oral endocrine therapy for breast cancer: a nursing perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Safety of exemestane in the Intergroup Exemestane Study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Menopausal symptoms and adjuvant therapy-associated adverse events

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitor-associated arthralgia syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Estrogen production and action

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Management of arthralgias associated with aromatase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Vitamin D deficiency: what a pain it is.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Prospective study of physical activity and risk of postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Aromatase inhibitors and bone loss: risks in perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Practical guidance for the management of aromatase inhibitor-associated bone loss

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Cardiovascular health and aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Estrogen and Cognitive Functioning in Women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1351-3

21 January 2018

Identifiers

10.1007/S10549-011-1351-3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

release_xj6lycpyijhb7ohtrx4vu5k2rm

1 reference

https://api.fatcat.wiki/v0/release/xj6lycpyijhb7ohtrx4vu5k2rm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37830371&oldid=1966911099"